Can Stem Cell Therapy Slow GA? - Summary - MDSpire

Can Stem Cell Therapy Slow GA?

Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.

  • By

  • VIVIENNE HAU, MD, PHD

  • July 15, 2026

  • 3 min

Share

Objective:

To evaluate the safety and efficacy of ASP7317, a human stem cell-derived retinal pigment epithelial cell therapy, in patients with advanced geographic atrophy.

Approach:
  • Study Design: Phase 1b trial assessing safety and efficacy of ASP7317.
  • Safety Assessment: Monitored for cellular graft failure, rejection, tumor growth, and intraocular pressure elevation.
  • Efficacy Assessment: Measured best-corrected visual acuity (BCVA) and geographic atrophy area stabilization.
  • Patient Feedback: Utilized Patient Global Impression of Change (PGIC) questionnaire to gauge patient perceptions.
Key Findings:
  • No significant safety concerns such as graft failure, tumor growth, or elevated intraocular pressure were observed.
  • BCVA improved in the small and medium cohorts over 52 weeks compared to the fellow eye, which showed deterioration.
  • Geographic atrophy area stabilization was noted over time.
  • Most patients reported their vision was the same or improved.
Interpretation:

ASP7317 demonstrated a favorable safety profile and potential efficacy in improving visual acuity and stabilizing geographic atrophy.

Limitations:
  • The study did not include a true control group.
  • The sample size was small.
Conclusion:

ASP7317 warrants further studies.

Sources:

Original Source(s)

Can Stem Cell Therapy Slow GA?

  • by VIVIENNE HAU, MD, PHD

  • July 15, 2026

Related Content

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

Myopia Patterns in Intermittent Exotropia

New findings indicate intermittent exotropia may influence binocular ocular growth patterns without significantly increasing myopia risk

  • July 15, 2026

  • 2 min